MedTrace Logo

Immune-Marker Platform for Patients With Advanced Lung Cancer

NCT07150598 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-09-08

No results posted yet for this study

Summary

The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.

The investigators aim to answer the following questions:

* Can the investigators successfully analyze immune markers and gene activity from small tumor samples (biopsies)?
* Are these markers connected to how well patients respond to immunochemotherapy and how their disease progresses?

What will participants do?

* Provide tumor tissue samples (biopsies) at key points: before treatment, about 6 weeks after starting immunochemotherapy, and if the cancer grows or treatment changes.
* Allow their tumor samples to be analyzed in the lab using advanced techniques to measure immune and genetic markers.
* Share clinical information (such as treatment response and disease progression) so investigators can study how it relates to these markers.

This study does not test a new drug or treatment.

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • NSCLC Stage IIIB~IV
  • NSCLC Non-small Cell Lung Cancer

Sponsors & Collaborators

  • Deutsche Krebshilfe e.V., Bonn (Germany)

    collaborator OTHER

  • Universitätsklinikum Köln

    collaborator OTHER

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Martin Wermke, Prof. Dr. · Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden

  • Jürgen Wolf, Prof. Dr. · Klinik I für Innere Medizin, CIO, Universitätsklinikum Köln

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-03-31
Completion
2027-06-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07150598 on ClinicalTrials.gov